Cai J, et al. - Researchers compared the efficacy of individual angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) on major renal outcomes in adults with diabetic kidney disease (DKD)—including end-stage renal disease, albuminuria/proteinuria (change in albuminuria/proteinuria, progression to macroalbuminuria and remission to normoalbuminuria), and doubling of serum creatinine levels. They performed a Bayesian-framework network meta-analysis with a random effects model and analyzed data from clinical trials of ACEIs or ARBs as monotherapy vs other conventional antihypertensive drugs or placebo. A total of 100 studies with data for 22,365 patients with DKD were included. According to findings, they found little or no differences in the effects of individual ACEIs and ARBs, at goal doses, on major renal outcomes.